Jacobs Levy Equity Management Inc. Invests $11.64 Million in Halozyme Therapeutics, Inc. $HALO

Jacobs Levy Equity Management Inc. acquired a new position in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 182,354 shares of the biopharmaceutical company's stock, valued at approximately $11,636,000. Jacobs Levy Equity Management Inc. owned approximately 0.15% of Halozyme Therapeutics at the end of the most recent quarter.

Several other large investors also recently made changes to their positions in HALO. Algert Global LLC acquired a new stake in shares of Halozyme Therapeutics in the 4th quarter valued at about $521,000. Baird Financial Group Inc. grew its stake in shares of Halozyme Therapeutics by 2.0% in the 4th quarter. Baird Financial Group Inc. now owns 11,119 shares of the biopharmaceutical company's stock valued at $532,000 after buying an additional 221 shares during the period. Captrust Financial Advisors grew its stake in shares of Halozyme Therapeutics by 24.3% in the 4th quarter. Captrust Financial Advisors now owns 29,862 shares of the biopharmaceutical company's stock valued at $1,428,000 after buying an additional 5,829 shares during the period. EP Wealth Advisors LLC grew its stake in shares of Halozyme Therapeutics by 8.5% in the 4th quarter. EP Wealth Advisors LLC now owns 6,769 shares of the biopharmaceutical company's stock valued at $324,000 after buying an additional 533 shares during the period. Finally, D. E. Shaw & Co. Inc. grew its stake in shares of Halozyme Therapeutics by 171.2% in the 4th quarter. D. E. Shaw & Co. Inc. now owns 831,414 shares of the biopharmaceutical company's stock valued at $39,750,000 after buying an additional 524,802 shares during the period. 97.79% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Halozyme Therapeutics

In other news, Director Bernadette Connaughton sold 4,000 shares of the business's stock in a transaction that occurred on Tuesday, September 2nd. The stock was sold at an average price of $73.68, for a total value of $294,720.00. Following the transaction, the director owned 46,952 shares in the company, valued at $3,459,423.36. The trade was a 7.85% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Helen Torley sold 20,000 shares of the business's stock in a transaction that occurred on Tuesday, August 12th. The stock was sold at an average price of $63.51, for a total value of $1,270,200.00. Following the completion of the transaction, the chief executive officer owned 733,719 shares in the company, valued at $46,598,493.69. The trade was a 2.65% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 124,000 shares of company stock worth $7,830,320 in the last 90 days. Insiders own 2.40% of the company's stock.

Halozyme Therapeutics Stock Down 0.8%

HALO stock traded down $0.63 during mid-day trading on Friday, reaching $76.90. 1,121,085 shares of the company traded hands, compared to its average volume of 1,930,531. The stock has a market cap of $8.99 billion, a price-to-earnings ratio of 17.60, a P/E/G ratio of 0.43 and a beta of 1.19. The company has a quick ratio of 7.01, a current ratio of 8.36 and a debt-to-equity ratio of 4.54. Halozyme Therapeutics, Inc. has a fifty-two week low of $42.01 and a fifty-two week high of $77.60. The firm's 50 day moving average price is $65.11 and its 200 day moving average price is $60.45.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last released its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $1.54 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.23 by $0.31. Halozyme Therapeutics had a return on equity of 150.85% and a net margin of 47.28%.The business had revenue of $325.72 million during the quarter, compared to the consensus estimate of $282.66 million. During the same quarter in the previous year, the business earned $0.91 EPS. The company's quarterly revenue was up 40.8% on a year-over-year basis. Halozyme Therapeutics has set its FY 2025 guidance at 6.000-6.400 EPS. As a group, equities research analysts predict that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts have recently commented on the company. The Goldman Sachs Group assumed coverage on Halozyme Therapeutics in a research note on Thursday, July 10th. They issued a "neutral" rating and a $55.00 target price for the company. Morgan Stanley raised their target price on Halozyme Therapeutics from $75.00 to $80.00 and gave the company an "overweight" rating in a research note on Monday, August 18th. Zacks Research upgraded Halozyme Therapeutics from a "hold" rating to a "strong-buy" rating in a research note on Tuesday, September 2nd. JMP Securities raised their target price on Halozyme Therapeutics from $78.00 to $91.00 and gave the company a "market outperform" rating in a research note on Wednesday, August 6th. Finally, HC Wainwright lifted their price target on Halozyme Therapeutics from $72.00 to $75.00 and gave the company a "buy" rating in a research note on Wednesday, August 6th. One investment analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, five have given a Hold rating and two have given a Sell rating to the company's stock. Based on data from MarketBeat.com, Halozyme Therapeutics has a consensus rating of "Hold" and a consensus target price of $67.11.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.